Related Experiment Videos

[ACEI/ARB use among high risk patients with coronary heart disease in China: a cross-sectional study]

Jia-min Liu1, Lei Ge, Jing Li

  • 1China Oxford Centre for International Health Research Cardiovascular Institute, Beijing, People's Republic of China.

Zhonghua Xin Xue Guan Bing Za Zhi
|May 9, 2013
PubMed

Insights

Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) are underused in high-risk coronary heart disease (CHD) patients in China. This highlights a gap between evidence-based guidelines and clinical practice for secondary prevention.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Context:

  • Coronary heart disease (CHD) is a leading cause of mortality globally.
  • Secondary prevention strategies are crucial for managing high-risk CHD patients.
  • Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) are recommended for secondary prevention in CHD.

Purpose:

  • To investigate the current utilization of ACEI/ARB in high-risk CHD patients in China.
  • To identify factors influencing ACEI/ARB prescription patterns in this population.

Summary:

  • A cross-sectional survey of 51 hospitals in China revealed that only 45.8% of high-risk CHD patients were prescribed ACEI/ARB.
  • ACEI/ARB use decreased over time post-diagnosis and was lower in patients with diabetes compared to those with hypertension.
  • Comorbid hypertension, male gender, history of myocardial infarction, and percutaneous coronary intervention (PCI) were associated with ACEI/ARB use.

Impact:

  • Findings indicate significant underutilization of ACEI/ARB for secondary prevention in Chinese CHD patients.
  • Addresses the gap between clinical evidence and practice, informing healthcare professionals and policymakers.
  • Highlights the need for targeted interventions to improve guideline adherence and patient outcomes.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...